ABBOTT LABORATORIES — Director's Dealing 2023

May 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-04-28

Reporting Person: STARKS DANIEL J (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-28	Common shares without par value	A	1816	—	Acquired	6875316	Direct
2023-05-02	Common shares without par value	S	46548	$110.97	Disposed	6828768	Direct
2023-05-02	Common shares without par value	S	3452	$111.75	Disposed	6825316	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-28	Option (right to buy)	$110.12	A	8136	Acquired	2033-04-27	Common Shares (8136)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	258	Indirect

Footnotes

F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

F5: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.